Published in Blood Weekly, March 30th, 2000
J.F. Liang and colleagues reported on their attempts in improving thrombolytic drug delivery in a study titled "A novel delivery system for tissue plasminogen activator," at a meeting of the American Association of Pharmaceutical Scientists in New Orleans, Louisiana, USA.
Major reasons for the lack of clinical applications of enzyme lie in the potential immunogenicity, as well as the indiscriminate nature of an enzyme in its action towards both target and normal substrate, they noted.
Liang et al. developed in their laboratory...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.